Login to Your Account

Idera Signs $421M Deal For TLR9 Cancer Agonists

By Trista Morrison

Thursday, December 20, 2007
The deal-making furor surrounding Toll-like receptors (TLRs) is continuing, with Merck KGaA agreeing to pay up to $421 million for worldwide rights in cancer indications to Idera Pharmaceuticals Inc.'s for TLR9 agonists. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription